Drug Information

Drug General Information
Drug ID
D0CY1B
Former ID
DCL000010
Drug Name
CYC116
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [522163]
Therapeutic Class
Anticancer Agents
Company
Cyclacel Limited
Structure
Download
2D MOL

3D MOL
Formula
C18H20N6OS
Canonical SMILES
CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4
InChI
1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23)
InChIKey
GPSZYOIFQZPWEJ-UHFFFAOYSA-N
PubChem Compound ID
6420138
PubChem Substance ID
11618518, 16832086, 24424536, 43014321, 46393965, 50521546, 99436925, 103652037, 103904403, 104120139, 114518369, 124757050, 125163854, 125329932, 125650062, 131480715, 134339467, 135685404, 135685405, 135685424, 136367344, 136367981, 136920315, 137276048, 141791974, 144115863, 152037316, 152258254, 152344039, 160647090, 162011811, 162037480, 162202552, 164194001, 170481285, 174561022, 180190851, 185965274, 188899569, 223653845, 223705256, 223964817, 228221334, 246870915, 249814521, 251963051, 252215210, 252451655, 252543304
Target and Pathway
Target(s) Aurora kinase B Target Info Inhibitor [550374]
Vascular endothelial growth factor receptor 2 Target Info Inhibitor [550374]
Aurora kinase A Target Info Inhibitor [550374]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
VEGF signaling pathway
Focal adhesion
Proteoglycans in cancerhsa04114:Oocyte meiosis
NetPath Pathway IL2 Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathway
Pathway Interaction Database Aurora B signaling
Signaling by Aurora kinases
Aurora C signaling
FOXM1 transcription factor network
Aurora A signalinghif2pathway:HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
VEGF and VEGFR signaling network
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY networkaurora_b_pathway:Aurora B signaling
Integrin-linked kinase signaling
PLK1 signaling events
Aurora A signaling
Reactome APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Separation of Sister Chromatids
Resolution of Sister Chromatid Cohesion
RHO GTPases Activate Formins
Mitotic PrometaphaseR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferationR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Regulation of PLK1 Activity at G2/M Transition
WikiPathways Mitotic Metaphase and Anaphase
Mitotic Prometaphase
Regulation of Microtubule Cytoskeleton
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
APC/C-mediated degradation of cell cycle proteinsWP306:Focal Adhesion
Nifedipine Activity
Cardiac Progenitor Differentiation
Signaling by VEGF
AngiogenesisWP437:EGF/EGFR Signaling Pathway
JAK/STAT
Gastric Cancer Network 1
Integrated Breast Cancer Pathway
APC/C-mediated degradation of cell cycle proteins
References
Ref 522163ClinicalTrials.gov (NCT00560716) A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 550374Clinical pipeline report, company report or official report of Cyclacel.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.